Article
Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.
Molecular cancer therapeutics - 1 Jul 2017
Gimenez-Xavier Pol, Pros Eva, Bonastre Ester, Moran Sebastian, Aza Ana, Graña Osvaldo, Gomez-Lopez Gonzalo, Derdak Sophia, Dabad Marc, Esteve-Codina Anna, Hernandez Mora Jose R, Salinas-Chaparro Diana, Esteller Manel, Pisano David, Sanchez-Cespedes Montse
Abstract excerpt
The development of resistance to tyrosine kinase inhibitors (TKI) limits the long-term efficacy of cancer treatments involving them. We aimed to understand the mechanisms that underlie acquired resistance (AR) to MET inhibitors in lung cancer. EBC1 cells, which have MET amplification and are sensitive to TKIs against MET, were used to generate multiple clones with AR to a MET-TKI. Whole-exome sequencing, RNA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.